Products with Anticancer bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN4999 | Timosaponin A3 |
| Timosaponin A3 triggers liver injury through inducing ROS generation and suppressing the expression of BA transporters, it has selectively cytotoxic for cancer versus normal cells. Timosaponin A3 can inhibit nuclear factor-kB and p38 signaling in TNF-a stimulated BV2 microglia cells, it has the therapeutic potential for various neurodegenerative diseases caused by inflammation. Timosaponin A3 also has application for reducing blood sugar and treating type-B diabete. | |
| BCN5006 | Scopolamine butylbromide |
| Scopolamine butylbromide is a competitive antagonist of muscarinic acetylcholine receptor (mAChR) with an IC50 of 55.3 ± 4.3 nM, it possesses anticholinergic, and anti-tumor effects, it used as an abdominal-specific antispasmodic agent. Scopolamine butylbromide is effective in preventing succinylcholine-induced bradycardia in infants and children. | |
| BCN5015 | Byakangelicol |
| Byakangelicol exhibits hepatoprotective activities on tacrine-induced cytotoxicity in Hep G2 cells, with EC(50) values of 112.7 +/- 5.35 microM. Byakangelicol may have therapeutic potential as an anti-inflammatory drug on airway inflammation, it can inhibit IL-1beta-induced PGE2 release in A549 cells; this inhibition may be mediated by suppression of COX-2 expression and the activity of COX-2 enzyme, it also can inhibit P-gp expressed. Byakangelicol shows a significant inhibition on the proliferation of cultured human tumor cells. | |
| BCN5018 | 20(R)-Ginsenoside Rg3 |
| 20(R)-Ginsenoside Rg3 has anticarcinogenic, neuroprotective, anti-aging and antifatigue activities, it has a wide spectrum of targets including caspase-3, MMP-2, MMP-9,HIF-1α,VEGF,IL-1,IL-6 and TNF-α. | |
| BCN5019 | Cucurbitacin IIA |
| Cucurbitacin IIa has anti-cancer, anti-bacterial, and anti-inflammatory effects, it can induce apoptosis and enhance autophagy; it also can disrupt the actin cytoskeleton and direct the cell to undergo PARP-mediated apoptosis through the inhibition of survivin downstream of JAK2/STAT3. | |
